Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news claude_news gdelt_news code_execution wikipedia

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi market on a 4-year average (2025-2028) of US measles cases ≥5,000, i.e., a cumulative total ≥20,000. The key empirical inputs are the final 2025 CDC case count, the 2026 year-to-date trajectory, and structural drivers (MMR coverage decline, loss of elimination status, vaccine policy under RFK Jr.). Market price plus arithmetic on required future-year counts will pin the estimate.

# Current state As of the research cutoff (~2026-08-03), the resolution mechanism is the arithmetic average of annual CDC-confirmed measles cases across 2025-2028 (4 years) being ≥5,000. 2025 finished at 2,289 confirmed cases (highest since 1991/92); 2026 year-to-date (through July 30) already stands at 2,371+, on pace to exceed 2025's full-year total well before year-end. Neither year is remotely close to 5,000/yr individually; hitting the 4-yr average threshold requires 2027-2028 (and the remainder of 2026) to sustain roughly 2-2.5x current annual levels for multiple consecutive years — a historically unprecedented compounding trajectory, not a single bad outbreak. # Timeline of key events - 2019-01 to 2019-12: Prior modern-era record, 1,274 cases (confirmed). - 2024 (full year): 285 cases (confirmed) — pre-surge baseline. - 2025-06: Utah/Arizona border-region outbreak begins (confirmed, per CIDRAP/AAP). - 2025 (full year): 2,289 confirmed cases, 48 outbreaks, 45 jurisdictions, 3 deaths — highest since 1992 (confirmed, CDC/AAP). - 2025-06-09: HHS Secretary RFK Jr. removes all 17 sitting ACIP members, appoints replacements (confirmed, Congress.gov CRS). - 2025-11: Americas region (PAHO) formally loses "endemic-measles-free" regional status; Canada (5,463 cases in 2025) cited as having lost elimination due to 12+ months continuous transmission (confirmed, PAHO/CIDRAP). - 2026-01: CDC implements overhauled childhood vaccine schedule (18→11 universally recommended diseases) (confirmed, later stayed by court) (reported, Congress.gov). - 2026 (court date TBD, per R48982): Court stays 2026 schedule change and stays appointments/votes of 13 RFK-appointed ACIP members, reverting schedule to May 2025 version (confirmed, Congress.gov CRS). - 2026-06-18/06-20: 2,104 cases confirmed across 41 states, 3 deaths total (confirmed, CDC/medicaldaily). - 2026-07-06: CDC update to 2,170 cases (confirmed, medicaldaily). - 2026-07-24/07-30: CDC confirms 2,318-2,371 cases, surpassing full-year 2025 total; described as worst year since 1991 (confirmed, CDC/UPI/NBC/ABC). - 2026 (ongoing, late July): Active major outbreaks — South Carolina (670, since declared over), Utah (~518-700+, still active statewide), Texas (182), plus newer Virginia and Pennsylvania hotspots (~134 cases) (confirmed/reported, CIDRAP/CDC map). - 2026-08-02/03: RFK Jr. publicly urges MMR vaccination amid record outbreak (confirmed, ABC/Yahoo). - 2026-11 (scheduled): PAHO Regional Verification Commission formally evaluates whether US retains measles elimination status; analysis (PNAS) finds US failing 4/7 elimination indicators, loss deemed "highly likely" (reported, CIDRAP/PNAS). # Event Kalshi market asking whether the 2025-2028 average annual US measles case count will be ≥5,000. # Outcomes to forecast Yes / No # Kalshi market anchor **Current YES price: 31%** (KXAVGMEASLESDJT-29-5000). 7-day change: -3pts; 30-day change: -1pt. Price range over 128 days: 28%-65% (has fallen substantially from earlier highs). Average daily volume ~170 contracts — thin but active. Trend is drifting downward, suggesting market is losing conviction in the ≥5,000 outcome as 2026 data comes in without reaching extreme levels. # Sub-question answers 1. **2025/2026 CDC totals** — 2025 final: 2,289 confirmed cases (highest since 1991/92). 2026 YTD (through 2026-07-30): 2,371+ confirmed, already exceeding all of 2025 [CDC/CIDRAP/NBC/ABC]. 2. **Required 2026-28 average** — With 2025 ≈2,300, remaining years must average ~5,900/yr (2.57x 2025 level, sustained) to hit the 4-yr average of 5,000 [code_execution Monte Carlo]. 3. **Historical base rate** — 2000-2024 annual counts were mostly in double-to-low-quadruple digits; prior max was 1,274 (2019); 2024 was only 285. 2025's 2,289 is unprecedented in the post-elimination era [claude_news/CDC]. 4. **Elimination status & outbreaks** — Not yet formally lost as of research date; PAHO review scheduled Nov 2026, with analysis (PNAS) calling loss "highly likely" (failing 4/7 indicators, transmission rate >1 on 285/376 days). Active large outbreaks ongoing in Utah (700+, statewide), Texas (182), with SC outbreak (670) since declared over, plus emerging VA/PA clusters [CIDRAP/medicaldaily]. 5. **Vaccine coverage/policy** — National kindergarten MMR coverage fell from 92.7% (2023-24) to 92.5% (2024-25), well below 95% target; ~286,000 kindergarteners unvaccinated; exemption rates hit record 3.6%. RFK Jr. removed entire ACIP (June 2025) and pushed a 2026 schedule overhaul, but a court stayed both the schedule change and ACIP appointments, reverting to May 2025 status quo [Congress.gov CRS/Healio/KFF]. 6. **Kalshi ladder implied distribution** — Only the 5,000 threshold market was surfaced (31% YES); no data returned for other rungs (1000/2000/10000), so a full distributional read isn't available from research, though 31% at the 5,000 level with declining trend implies markets see this as a plausible-but-not-majority outcome. # Key facts (high-confidence, factual) 1. [CDC/AAP] 2025 full year: 2,289 confirmed cases, 3 deaths. 2. [CDC/NBC/ABC] 2026 YTD (7/30): 2,371+ cases, surpassing 2025. 3. [Congress.gov] Court stayed 2026 vaccine schedule overhaul and RFK-appointed ACIP members. 4. [CIDRAP/PNAS] US "highly likely" to lose elimination status; PAHO formal review Nov 2026. 5. [KFF/Healio] Kindergarten MMR coverage 92.5% (2024-25), below 95% target; record exemption rates. 6. [code_execution] Reaching 5,000 4-yr average requires ~2-2.6x sustained annual growth for 2026-2028 vs. 2025. # Cross-market signals - Kalshi related: Only this ticker found in series/keyword search; no sibling threshold markets (1000/2000/10000) surfaced despite question implying a ladder — data gap. - Polymarket: No matching markets found (0/100 scanned). - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - AAP president: 2026 is "the worst year for measles since 1991" [claude_news]. - CIDRAP/PNAS analysts: loss of elimination status "highly likely" in 2026, driven by sustained >1 transmission rate for most of the year. - code_execution Monte Carlo: realistic probability range ~15-40% under historically-grounded growth assumptions (1.0-1.3x/yr); only sustained 1.5-2x/yr compounding growth pushes probability toward 50-85%. # Directional lean per outcome - **Yes (≥5000 avg)**: Supported by record 2025/2026 totals, declining vaccination coverage, elimination-status loss trajectory, ongoing multi-state outbreaks (UT, TX, new VA/PA clusters), and vaccine-policy turmoil (ACIP overhaul attempts). Opposed by: math requires ~2.5x sustained annual growth for 3 straight years — no historical precedent for such multi-year compounding (even 2025's surge was ~8x prior year's 285, a one-time jump, not sustained); court has already stayed the most aggressive policy change; Kalshi price trending down (65%→31%). - **No (<5000 avg)**: Supported by base rates (any single year even at "record" levels has topped out near 2,400), thin evidence of accelerating rather than plateauing outbreaks, and current Kalshi pricing (69% implied No). Opposing: uncertainty remains high given only ~1.5 years of the 4-year window observed; a large new outbreak or continued elimination-status loss could still shift trajectory. # Gaps / unknowns - Full-year 2026 final total not yet known (only through July). - No visibility into 2027-2028 case trajectories or policy environment. - Missing Kalshi data for sibling threshold markets (1000/2000/10000) to triangulate implied distribution. - Uncertain whether formal elimination-status loss (Nov 2026) materially changes CDC counting/reporting methodology or case growth rate. # Calibration anchors - Kalshi current YES price: 31% (down from historical range high of 65%, trending down over 7/30 days) — anchor. - Historical precedent: 2019 record (1,274) was ~13x the 2000-2018 typical annual count but still nowhere near 5,000; 2025 (2,289) nearly doubled 2019; sustained multi-year compounding to 5,000+/yr has no US precedent since pre-elimination era (pre-2000).

1. Both forecasters converge almost identically (27% and 26%) using near-identical reasoning, suggesting insufficient independent exploration of tail scenarios — e.g., neither seriously models the possibility that loss of elimination status (PNAS: "failing 4/7 elimination indicators," R>1 on 285/376 days) represents a genuine regime shift to endemic transmission rather than a one-off outbreak, which is exactly the mechanism that produced Canada's 5,463/yr. 2. Forecast 1's math ("remaining two years would need to average ~7,000/yr") implicitly assumes 2026 lands at 3,000-4,500 and only treats 2027-2028 as open, while the brief's own Monte Carlo frames the hurdle as ~5,900/yr average across all of 2026-2028 combined — this inconsistency in how much of 2026 is "already spent" versus still uncertain is not reconciled between the two forecasts. 3. Both anchor heavily on the Kalshi 31% price despite the brief noting "thin volume (~170 contracts/day)" and a wide historical range (28%-65%), meaning the anchor itself may carry limited informational value from a shallow market — neither forecast discounts for this illiquidity when justifying only a small deviation below it. 4. Neither forecast addresses seasonality: measles outbreaks historically accelerate with school-year start (fall/winter) and holiday travel, yet the July 2026 YTD trajectory is being extrapolated somewhat statically without weighting for a plausible autumn surge given ongoing Utah/Texas/VA/PA outbreaks. 5. Both treat "2-2.5x sustained growth has no precedent" as decisive, but understate that 2025→2026 already delivered roughly a doubling YoY pace (2,289 full-year vs. 2,371 through only 7 months) — i.e., the "unprecedented" compounding is arguably already underway in year one of the required window, which should raise (not just acknowledge) the probability mass rather than being treated as a pure headwind. 6. Neither forecast flags the total absence of sibling Kalshi threshold markets (1000/2000/10000) as a real information gap that prevents cross-checking whether 31% is consistent with the market's implied full distribution — both simply accept the single data point without noting this limits confidence in "anchoring appropriately."

30% (medium confidence)

Yes: 30% No: 70%

Resolution needs ~20,000 total confirmed cases across 2025-2028; with 2025 locked at 2,289 and 2026 at 2,371 through July, plausible 2026 finish of ~3,300-4,200 (2025's second half added ~1,000 cases, and fall school-year/holiday transmission is a real upside factor the base forecasts under-weighted) leaves 2027-2028 needing roughly 6,500-7,000/yr each. That is unprecedented post-elimination, but not physically implausible given Canada's 5,463 in 2025, PNAS finding R>1 on 285/376 days, failure of 4/7 elimination indicators, MMR kindergarten coverage at 92.5% with record 3.6% exemptions, and a likely formal loss of elimination status in Nov 2026 — i.e., a genuine regime shift toward endemic transmission rather than repeated one-off outbreaks. Offsetting this: the court stay reverted the most aggressive schedule/ACIP changes, RFK Jr. is now publicly urging MMR, outbreak dynamics tend to burn through susceptible clusters and plateau, and the market has decayed from 65% to 31% precisely as 2026 came in 'record but not extreme.' The critique is right that both forecasters clustered slightly below a thin-but-informative anchor without modeling the endemic-transmission tail, so I move back to roughly the market price rather than below it.

Total pipeline time: 310.9s